Business Wire

AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue

9.3.2026 08:30:00 CET | Business Wire | Press release

Share

Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement

AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/

AMINA, 21X and Tokeny partner for end-to-end solution

Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset custody with onchain issuance and liquid secondary markets.

The partnership comes as tokenisation transitions from pilot programmes to deployed financial infrastructure. Real-world assets (RWAs) onchain have grown from approximately $5 billion in 2022 to over $24 billion by mid-2025, with year-end estimates exceeding $38 billion. Including stablecoins, tokenised assets already surpass $330 billion in value.

The combined tokenisation infrastructure connects three layers:

  • AMINA provides institutional-grade custody and banking for the underlying traditional assets — government bonds, corporate securities, treasury bills and other financial instruments — and serves as listing sponsor, guiding issuers through the process of bringing tokenised products to market.
  • Tokeny (an Apex Group company with over $3.5 trillion in assets serviced) provides the enterprise-grade tokenisation platform, handling smart contract deployment and automated compliance controls via the ERC-3643 standard.
  • 21X, licensed by German financial market authority BaFin with the contribution of ESMA (the EU’s financial markets regulator and supervisor), provides the regulated trading and settlement venue for the primary and secondary market enabling smart contract-based trading and atomic settlement of tokenized financial instruments.

Together, this infrastructure addresses two persistent barriers to institutional tokenisation: the lack of regulated secondary market liquidity, and the absence of a seamless pathway from traditional asset ownership to onchain distribution.

AMINA’s Chief Product Officer, Myles Harrison, said: “Institutional investors have rightly waited for tokenisation infrastructure that meets their governance and compliance standards. By partnering with 21X and building on our collaboration with Tokeny, we’ve assembled the complete infrastructure — from banking custody of underlying assets through to onchain issuance and exchange trading. For institutions looking to access tokenised securities, this is the pathway they’ve been waiting for.”

Max J. Heinzle, CEO, 21X, added: “We are proud to welcome AMINA to the 21X ecosystem as a premier listing sponsor. With our secondary market now fully operational, the addition of a world-class institutional partner like AMINA is a significant milestone. The Swiss bank’s heritage and pioneering work in digital assets provide the exact blend of rigour and innovation required to scale our platform. Together, we are making the trading and settlement of tokenised equities, bonds, and funds a seamless reality for the global financial community.”

The partnership builds on AMINA’s track record as a pioneer in regulated crypto banking. Since receiving its FINMA licence in 2019, AMINA has expanded across four jurisdictions, including Switzerland, Abu Dhabi, Hong Kong, and the EU (via Austria) and maintained a zero-default lending track record over more than six years. 21X’s exchange, which went live in September 2025 as the world’s first fully regulated blockchain-based trading and settlement venue for tokenised securities, operates on the Polygon blockchain and the Stellar network with partners including Chainlink, Circle, and SBI Digital Markets, enabling smart contract-based matching and settlement that eliminates the need for central securities depositaries and clearing intermediaries.

Certain products and services may not be available to all clients based on legal and regulatory considerations.

About AMINA — Crypto. Banking. Simplified.

Founded in April 2018 and established in Zug (Switzerland), AMINA Bank AG is a pioneer in the crypto banking industry. In August 2019, AMINA Bank AG received the Swiss Banking and Securities Dealer License from the Swiss Financial Market Supervisory Authority (“FINMA”). In February 2022, AMINA Bank AG, Abu Dhabi Global Markets (“ADGM”) Branch received Financial Services Permission from the Financial Services Regulatory Authority (“FSRA”) of ADGM. In November 2023, AMINA (Hong Kong) Limited received its Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) licenses from the Securities and Futures Commission (“SFC”). In October 2025, the firm’s Type 1 license was further approved for uplift to include digital asset dealing services for Professional Investors under Hong Kong’s digital asset regulatory framework. In October 2025, AMINA (Austria) AG (“AMINA EU”) received its CASP license from Austria’s Financial Market Authority (“FMA”) under the Markets in Crypto-Assets (MiCAR) framework.

CVVC Global Report and CB Insights named AMINA as one of the Top 50 Companies within the blockchain ecosystem. In 2023, AMINA won the European WealthBriefing Award in the Digital Assets Solution, Fund Manager category. AMINA was most recently recognised as Institutional Digital Asset Innovation of the Year at the Hedgeweek® Global Digital Assets Awards 2025.

To learn more about AMINA, visit www.aminagroup.com.

About 21X

21X is a Frankfurt-based investment firm at the forefront of revolutionizing capital markets through the use of blockchain technology. On 8th September 2025, 21X fully opened the first ever fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the EU, positioning the company as a leader in the transition from traditional to tokenized asset-based capital markets. 21X enables atomic trading without counterparty risk through smart contract-based issuance, trading and settlement of tokenized stocks, bonds and funds.

See the short explainer video on 21X and our blockchain-based exchange here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309758719/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye